Sudeep Pharma · NSE: SUDEEPPHRM · BSE: 544619
Q2 FY26 results · Jul–Sep 2025
Sudeep Pharma reported revenue from operations of ₹162.67 crore and net profit of ₹46.78 crore for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 162.67 | — | — | — | — |
| Other income | 10.17 | — | — | — | — |
| Total income | 172.83 | — | — | — | — |
| Profit before tax | 59.53 | — | — | — | — |
| Net profit for the period | 46.78 | — | — | — | — |
| Attributable to shareholders of the company | 45.75 | — | — | — | — |
| EPS, basic (₹) | 4.20 | — | — | — | — |
| Net margin (%) | 28.8 | — | — |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 87.88 | — | — | — | — |
| Other income | 12.83 | — | — | — | — |
| Total income | 100.71 | — | — | — | — |
| Profit before tax | 39.90 | — | — | — | — |
| Net profit for the period | 29.74 | — | — | — | — |
| EPS, basic (₹) | 2.67 | — | — | — | — |
| Net margin (%) | 33.8 | — | — |
Consolidated
- Filed with BSE
- 19 Dec 2025, 15:55 IST
- Board meeting
- 19 Dec 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 19 Dec 2025, 15:55 IST
- Board meeting
- 19 Dec 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE